During the congress, held at the end of 2025 in Orlando (USA), specialists from Einstein's Oncology and Hematology shared the latest news about hematological diseases and treatments. On this page, you will find the main contents, analyses, and insights presented
Einstein at the 67th
ASH Annual
Meeting & Exposition
Einstein at the Annual Meeting of the American Society of Hematology (ASH)
Video clips and panels with specialists, published on the Hematolog educational platform and Einstein's organizational channels
Exclusive partnership with ASH in ASH TODAY — the official educational program, endorsed by the American Society of Hematology, for post-congress content dissemination
Access to the 42 papers submitted by the Einstein team, three of which were awarded by ASH
Einstein Oncology and Hematology
For 70 years, Einstein has advanced the mission of not only treating but transforming lives. Voted the best hospital in Latin America and the 22nd in the world by Newsweek, it houses Einstein’s Oncology and Hematology. The center is an international reference in onco-hematological care and is recognized as the 17th best oncology service in the world and the 1st in Latin America
The center is part of the organization's care chain and brings together infrastructure, advanced therapies, and patient-oriented care in both private and public health
.png)
Recognized Excellence
The Einstein Hematology, Bone Marrow Transplant (BMT), and Cellular Therapy Program serves patients with malignant blood diseases such as leukemias, lymphomas, and multiple myeloma, or benign conditions such as acquired and congenital anemias, purpuras, and coagulopathies. In addition to bringing together a specialized team responsible for planning and executing procedures, the center offers infrastructure that includes pathology, hematology, histocompatibility, and microbiology laboratories
In addition, the organization offers the hemotherapy service, responsible for all transfusion care, as well as the collection, separation, and cryopreservation of hematopoietic stem cells
The results presented follow standards comparable to national and international reference centers, according to the 2025 Value Dossier
.png)
Highlights
Over 1,600 bone marrow transplants
Multidisciplinary care from diagnosis, with a team of specialists in hematology, oncology, nutrition, psychology, dentistry, physical therapy, integrative medicine, infectious diseases, cardiology, neurology, intensive care, and other patient support areas
Pioneering Brazilian study using CAR-T therapy for the treatment of lymphomas and leukemias, with authorization from the National Health Surveillance Agency (Anvisa)
Research-based practice in advanced therapies, precision medicine, and minimally invasive procedures
International Patient Support Center (CAPI), responsible for following patients and families throughout all stages of their journey, with individualized support and organized access to consultations, exams, and in-patient care
Hematolog – a free digital platform aimed at disseminating knowledge and connecting professionals in the fields of hematology, hemotherapy, bone marrow transplantation, and cellular and gene therapies
Annual review courses in hematology, hemotherapy, and cellular therapy
A new hub: excellence with international standards
Einstein is beginning the implementation of the Center for Advanced Therapies in Oncology and Hematology, located in São Paulo. The project is under construction and covers an area of 65,000 m², and will house qualified professionals and the necessary resources for humanized medicine
Follow the content produced by Einstein at ASH
Stay updated with the highlights of the congress
Check out the articles of the awarded studies
HLA and non-HLA factors in haploidentical donor selection: Insights from a brazilian single-center study
More than a bulk: higher incidence of venous thromboembolism (VTE) in patients with primary mediastinal B-cell lymphoma compared to patients with bulky mediastinal Hodgkin lymphoma
Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin’s lymphoma patients with an interim PET deauville score of 4